$AQST News

Aquestive Therapeutics: Potential Catalyst On The Horizon

Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript

Aquestive Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Aquestive Therapeutics Files Prospectus For Offering 230,271 Common Shares On Behalf Of Selling Shareholders

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?

Does US manufacturing give drugmakers a speed edge?

Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval

The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...

Aquestive Therapeutics Q1 Earnings Call Highlights

Aquestive Therapeutics, Inc. Q1 2026 Earnings Call Summary

Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript

Aquestive Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript

Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics

Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates